Curtana Pharmaceuticals, Inc. logo

Curtana Pharmaceuticals, Inc.

Curtana Pharmaceuticals is a developer of molecule therapeutics for the treatment of glioblastoma and brain cancers. Curtana Pharmaceuticals is a biopharma company developing first-in-class, small molecule therapeutics that are highly specific for cancer stem cells in the central nervous system for the treatment of glioblastoma (GBM) and other brain cancers.

In Sep. 2013, acquired worldwide development rights of CT-179 and signs a license agreement with the University of California, to further develop the molecue for the treatment of GBM and other cancers.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://www.curtanapharma.com
Founded2013
Disease Focus
Development Stage
STOCK CODENon Listed
Address
1624 Headway Circle, Suite 100,TX 78754
Austin
United States
Email
Contact Number

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/curtana-pharmaceuticals” connections=”true” suffix=””]

In Oct. 2014, Curtana secured NCI-NIH STTR Phase I Grant worth $225,000 USD to further develop CT-179. Also in Aug 2014 Curtana recieved $7.6 Mn product development grant funded by the Cancer Prevention and Research Institute of Texas (CPRIT).